Given synergistic effects of ganetespib + lapatinib on cell growth inhibition and apoptosis induction, and the regulatory role that RTK signaling plays in these cellular responses, we further explored whether the combination treatment of ganetespib and lapatinib enhanced RTK signaling inhibition in ErbB2+ breast cancer cells. Here, ERBB2 is linked to breast carcinoma.